Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study - Xu, Junyu; Zhang, Yifei; Li, Yiming; Zhao, Xia; Zhou, Weiwei; Loghin, Corina; Tham, Lai San; Cui, Xuewei; Cui, Yimin; Wang, Weiqing (Advances in therapy, 2022)
Keywords: Blood Glucose; Cardiology; China; Diabetes Mellitus, Type 2 - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Endocrinology; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - analogs & derivatives; Healthy Volunteers; Humans; Hypoglycemic Agents - adverse effects; Immunoglobulin Fc Fragments - adverse effects; Internal Medicine; Medicine; Medicine & Public Health; NCT; NCT01667900; Oncology; Original Research; Pharmacology/Toxicology; Recombinant Fusion Proteins - adverse effects; Rheumatology; China; Dulaglutide; Phase I study; Chinese participants